Antti Roine, M.D., from the University of Tampere in Finland, and colleagues investigated the ability of an electronic nose (ChemPro 100-eNose) to discriminate prostate cancer from benign prostatic hyperplasia using urine sample headspace.
Performance was tested with samples from 50 patients with confirmed prostate cancer scheduled to undergo robotic assisted laparoscopic radical prostatectomy and 24 samples from 15 patients with benign prostatic hyperplasia scheduled to undergo transurethral resection of the prostate. Urine samples were provided preoperatively, and those with benign prostatic hyperplasia also provided samples postoperatively to be used as a pooled control population.
The researchers found that the eNose reached a sensitivity of 78 percent and a specificity of 67 percent using leave-one-out cross-validation. The area under the receiver operating characteristic curve was 0.77.
“The electronic nose is capable of rapidly and noninvasively discriminating prostate cancer and benign prostatic hyperplasia using urine headspace in patients undergoing surgery,” the authors write.
One author disclosed financial ties to Amgen, Astellas, Sanofi-Aventis, and Bayer.